CompletedNot Applicable

East New Britain Province Monitoring & Evaluation

Papua New Guinea12,930 participantsStarted 2019-09-17

Plain-language summary

While tremendous progress towards elimination of lymphatic filariasis (LF) has been made in the 20 years since the 1997 Fiftieth World Health Assembly, it is unlikely the goal of eliminating LF as a public health problem by 2020 will be achieved. As of 2016, it was estimated that 856 million people are still living in areas with ongoing transmission of LF and require mass drug administration (MDA) \[1\]. Of the 52 countries that remain endemic and require MDA, 22 (42%) have not started MDA in all endemic implementation units (IUs) \[1\]. In addition, several countries have found that, despite completing the required number of treatment rounds, the response to the present MDA regimen has been suboptimal in some IUs, requiring additional rounds of MDA.

Who can participate

Age range5 Years – 80 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * All individuals ages 5 years to 80 years living in selected villages will be eligible to enroll. * Must live in the villages for at least 12 months Exclusion Criteria: * Minors ages 4 and under will not be eligible to enroll. * Lived in selected village for less than 12 months.

What they're measuring

To determine the presence of W. bancrofti microfilariae

Timeframe: 3 years

To determine the presence of W. bancrofti circulating antigen

Timeframe: 3 years

Trial details

NCT IDNCT04124250

SponsorUniversity Hospitals Cleveland Medical Center

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2024-01-01

View on ClinicalTrials.gov More Lymphatic Filariasis Elimination by Mass Drug Administration trials